Almost all previous clinical trials and retrospective studies suggest the use of pertuzumab in addition to the use of trastuzumab in neoadjuvant settings for HER2-positive breast cancer female patients to achieve a better pCR. The gene discussed is ERBB2; the disease is breast carcinoma.